Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism

Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth was only 5.3% and adjusted EPS declined 2.5% year-over-year. Management targets double-digit growth by the decade's end, yet consensus forecasts only ~6% EPS CAGR, and valuation multiples require aggressive growth assumptions. Stelara's patent cliff and high valuation multiples (30.4x earnings, 36.0x FCF) raise risk, while oncology and MedTech are key growth drivers to monitor.

My last article about Johnson & Johnson ( JNJ ) was published in October 2025. Back then, I argued that the stock was getting slowly overpriced, and I rated the stock as a “Hold” and did not see it